New hope for tough lymphoma: experimental drug KK2223 enters human testing
NCT ID NCT07192471
First seen Nov 01, 2025 · Last updated May 10, 2026 · Updated 33 times
Summary
This early-phase study tests a new drug called KK2223 in about 72 adults with T-cell lymphoma that has returned or not responded to prior therapy. The main goals are to find a safe dose and understand side effects. Participants will receive the drug and be closely monitored for safety and early signs of tumor shrinkage.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for T-CELL NHL (PTCL OR CTCL) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
AOU Citta' della Salute e della Scienza di Torino Ospedale Molinette, Ematologia Universitaria
Torino, 10126, Italy
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Azienda Ospedaliera Papa Giovanni XXIII - Ematologia
Bergamo, 24127, Italy
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Azienda Ospedaliero Universitaria di Bologna IRCCS (Policlinico di Sant'Orsola) - Ematologia
Bologna, 40138, Italy
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Beth Israel Deaconess Medical Center - Research
Boston, Massachusetts, 02215, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Clinica Universidad de Navarra - Hematología
Pamplona, Navarre, 31008, Spain
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Clinica Universidad de Navarra - Hematología y Hemoterapia
Madrid, 28027, Spain
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Hackensack University Medical Center - John Theurer Cancer C - Lymphoma Division
Hackensack, New Jersey, 07601-2105, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Hospital Clinic De Barcelona - Hematología
Badalona, Barcelona, 8036, Spain
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Institut Català d'Oncologia (ICO) - ICO L'Hospitalet - Hematologia
L'Hospitalet de Llobregat, Barcelona, 8907, Spain
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Istituto di Candiolo, IRCCS - Oncologia Medica ed Ematologia
Candiolo, Torino, 10060, Italy
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Memorial Sloan Kettering Cancer Center
New York, New York, 10021-6007, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Stanford University School of Medicine
Stanford, California, 94305, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
The University of Texas - MD Anderson Cancer Center
Houston, Texas, 77030, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
University of California, Irvine Medical Center - Hematology/Oncology
Orange, California, 92868, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Washington University School of Medicine - Oncology Hospital - Public
St Louis, Missouri, 63110, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.